Intro: Indian pharma companies expect a 12% revenue growth this quarter, though profits may drop due to drug patent expirations.
NEW DELHI
India’s major healthcare and pharmaceutical companies are bracing for a modest finish to the fiscal year.
A new report suggests that while revenue will likely grow by a steady 12% this quarter, actual profits are expected to take a hit. Net earnings across the sector could drop by as much as 14 percent compared to the same time last year.
The primary reason for this dip is the “loss of exclusivity” for several major drugs, most notably the cancer medication Revlimid. Big industry names like Dr. Reddy’s, Cipla, and Sun Pharma are feeling the pinch as their special rights to sell these expensive treatments end. For Dr. Reddy’s in particular, this change could lead to a sharp decline in earnings as the massive profits from that specific drug begin to vanish.
Global tensions are also adding to the pressure. The ongoing conflict between the US and Iran has caused shipping and raw material costs to rise. While a stronger US dollar helps Indian exporters, those gains are being canceled out by expensive freight. This could force companies that make active ingredients to raise their prices soon.
On a positive note, government regulators are keeping a close watch on the booming market for weight-loss and diabetes drugs. As cheaper versions of these popular treatments prepare to enter the Indian market, health officials are stepping up safety checks. This ensures that as these life-changing medicines become more affordable for everyone, they remain safe for public use.
